Allogene Therapeutics(ALLO)
Focus: Allogene Therapeutics is a public biotechnology company focused on developing allogeneic CAR-T cell therapies for hematologic malignancies, autoimmune diseases, and solid tumors. The company operates at mid-cap scale with 1,001-5,000 employees and is headquartered in South San Francisco.
Profile data last refreshed 13h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1001-5000
Open Jobs
18+1 this month
Stable — net +1 jobs in 30d
8 added, 7 removed. Backfill posture.
Should You Work at Allogene Therapeutics?
AI assessmentAllogene is a high-risk, high-potential bet for scientists and development professionals willing to tolerate near-term financial uncertainty in exchange for exposure to cutting-edge allogeneic CAR-T science.
Why Work Here
- Leading position in allogeneic CAR-T technology, a differentiated approach to cell therapy with potential to solve key manufacturing and accessibility challenges versus autologous therapies.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
13 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$22K
Pipeline & Clinical Trials
allogeneic CAR T cell therapy
Hematologic MalignanciesFollow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
Hematologic MalignanciesClinical Trials (1)
Help build intelligence for Allogene Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.